AFC Gamma's CEO sees Sunburn poised to gain more market share in Florida and profit from the industry's shift to mainstream consumer goods. Sunburn's CEO sees this as a chance to bolster their balance sheet, expand operations, and enhance Sunburn while awaiting potential catalysts.
AFC Gamma's CEO, Daniel Neville, expressed excitement about the two loans, stating they align with the company's strategy to invest in high-quality commercial real estate deals that provide compelling risk-adjusted returns.
Tannenbaum expects Neville's knowledge and leadership in the cannabis sector to boost AFC Gamma, particularly in managing cannabis credits. Neville sees growth potential for AFC Gamma through capital deployment and expanded platforms.
AFC Gamma股票讨论区
新增数据:23Q3,23Q4,净利润连续萎缩,Q4受信贷损失准备金影响转为亏损。
2023年净利润萎缩到0.21亿,市盈率为11.5,3年平均净利0.26亿对应市盈率9.3,股息率17%,回报率吸引力不大。
10 please
2021年上市,股息率TTM为16.5%,上市后发放比较稳定,市净率目前0.79。
2022年营收增长87.9%,净利润增长71.1%,2023上半年营收萎缩14.9%,净利润增长3%。
市盈率TTM为7.34,市盈率7.3,按近两年平均净利0.28亿计算,市盈率为9.5,不算太高。
综合来看可以谨慎选择(⭐️)
专栏Today's pre-market stock movers: ARRY, RIOT, MRNA, NVAX and more
• $Array Technologies(ARRY.US)$ +12.87% (also names new CEO)
• $Tufin软件科技(TUFN.US)$ +43.41% (enters into definitive agreement to be acquired by Turn/River Capital in a $570 million transaction; TUFN shareholders will receive $13.00/share in cash)
• $Citius Pharmaceuticals(CTXR.US)$ +10.87% (reported topline results from the pivotal Phase 3 trial of I/ONTAK)
• $BioXcel Therapeutics(BTAI.US)$ +19.22% (FDA ha...
暂无评论